DBV Technologies | DBVT - Nettoeinkommen

Aktienkurs
22.20
Täglich Wechseln
-0.59 -2.59%
Monatlich
4.42%
Jährlich
395.95%
Q1 Prognose
20.46




Nettoeinkommen Veränderung Datum
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
Amarin USD -7.74M 6.4M 2025-09
BioCryst Pharmaceuticals USD -88.88M 74.85M 2024-12
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
DBV Technologies USD -33.16M 8.71M 2025-09
Esperion Therapeutics USD -29.52M 32.4M 2024-09
Galectin Therapeutics USD -12.37M 880K 2024-06
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Incyte USD 299.28M 124.89M 2025-12
Insmed USD -328.48M 41.54M 2025-12
Ionis Pharmaceuticals USD -229M 100.39M 2025-12
Neurocrine Biosciences USD 209.5M 102M 2025-09
PTC Therapeutics USD -134.96M 150.86M 2025-12
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
United Therapeutics USD 364.3M 25.6M 2025-12